HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoCalendarPricing
Theme 		Help

Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

Open in Screener

DVAX

Dynavax Technologies Corp

Last Close
Feb 09  •  04:00PM ET
15.50
Dollar change
0.00
Percentage change
0.00 %
Healthcare • Drug Manufacturers - Specialty & Generic • USA • NASD
Peers: JNJ PFE MRNA GILD BNTX AZN-D REGN NVAX VIR VXRT
 | Held by: VTI VXF VTWO VIOO VHT VIOV VTWG VTHR CSA CSF
Index- P/E- EPS (ttm)-0.38 Insider Own0.81% Shs Outstand117.36M Perf Week0.00%
Market Cap1.82B Forward P/E- EPS next Y- Insider Trans-69.87% Shs Float116.47M Perf Month-0.64%
Enterprise Value1.46B PEG- EPS next Q- Inst Own99.70% Short Float8.41% Perf Quarter37.66%
Income-43.40M P/S5.51 EPS this Y- Inst Trans1.50% Short Ratio3.12 Perf Half Y45.95%
Sales330.51M P/B3.41 EPS next Y- ROA-4.32% Short Interest9.79M Perf YTD0.78%
Book/sh4.55 P/C2.81 EPS next 5Y- ROE-7.14% 52W High15.73 -1.46% Perf Year17.87%
Cash/sh5.52 P/FCF22.60 EPS past 3/5Y-27.72% - ROIC-5.57% 52W Low9.20 68.48% Perf 3Y40.91%
Dividend Est.- EV/EBITDA78.24 Sales past 3/5Y-14.08% 51.08% Gross Margin83.17% Volatility0.23% 0.40% Perf 5Y46.23%
Dividend TTM- EV/Sales4.42 EPS Y/Y TTM-310.39% Oper. Margin3.16% ATR (14)0.11 Perf 10Y-14.88%
Dividend Ex-Date- Quick Ratio6.94 Sales Y/Y TTM26.73% Profit Margin-13.13% RSI (14)76.00 Recom1.00
Dividend Gr. 3/5Y- - Current Ratio7.62 EPS Q/Q81.60% SMA20-0.38% Beta0.93 Target Price16.00
Payout0.00% Debt/Eq0.54 Sales Q/Q17.67% SMA5012.55% Rel Volume0.00 Prev Close15.50
Employees405 LT Debt/Eq0.46 EarningsNov 05 AMC SMA20038.23% Avg Volume3.14M Price15.50
IPOFeb 19, 2004 Option/ShortYes / No EPS/Sales Surpr.66.53% 0.93% Trades Volume0 Change0.00%
Date Action Analyst Rating Change Price Target Change
Feb-11-25Downgrade Goldman Neutral → Sell $15 → $12
Feb-01-24Initiated Goldman Neutral $20
Sep-27-22Initiated JMP Securities Mkt Outperform $22
Jan-06-22Resumed Goldman Buy $38
Aug-06-21Initiated Goldman Buy $19
Aug-07-20Reiterated H.C. Wainwright Buy $14 → $12
Aug-03-20Reiterated H.C. Wainwright Buy $12 → $14
Jun-15-20Initiated Evercore ISI Outperform $14
Oct-18-19Initiated H.C. Wainwright Buy $13
Jul-11-19Upgrade Cantor Fitzgerald Neutral → Overweight $20
Show Previous Ratings
Feb-04-26 06:15PM
Ciena Set to Join S&P 500; Arrowhead Pharmaceuticals to Join S&P MidCap 400; ADT and OneSpaWorld Holdings to Join S&P SmallCap 600
(PR Newswire)
Jan-29-26 11:21AM
Sanofi Beats on Q4 Earnings, Expects Profitable Growth in 2026
(Zacks)
Jan-14-26 10:57AM
Jim Cramer Highlights Sanofi's Bid for Dynavax
(Insider Monkey)
Jan-06-26 10:50AM
Halper Sadeh LLC Encourages DBRG, FOLD, DVAX Shareholders to Contact the Firm to Discuss Their Rights
(PR Newswire)
Dec-30-25 10:20AM
Halper Sadeh LLC Encourages DVAX, CWAN, DBRG Shareholders to Contact the Firm to Discuss Their Rights
(PR Newswire)
05:28AM Loading…
Dec-29-25 05:28AM
Sanofi Agrees to Buy Dynavax for $2.2 Billion After FDA MS Drug Rejection
(GuruFocus.com)
Dec-26-25 02:56PM
Christmas Week Brings S&P 500 Records, Tech Volatility
(Schaeffer's Research)
06:07AM
S&P Futures Muted in Thin Post-Christmas Trade
(Barchart)
03:08AM
Company News for Dec 26, 2025
(Zacks)
Dec-25-25 10:40AM
Dynavax (DVAX) Rockets 38% on Sanofi $2-Billion Merger
(Insider Monkey)
12:47AM
Asian shares are mixed after US stocks drift to more records
(Associated Press Finance)
Dec-24-25 03:55PM
Why Dynavax Stock Soared Today
(Motley Fool) +38.19%
02:23PM
Stocks End Mildly Higher as Bullish Sentiment Continues
(Barchart)
01:24PM
How major US stock indexes fared Wednesday, 12/24/2025
(Associated Press)
01:04PM
Sanofi To Buy Vaccine Maker Dynavax For $2.2 Billion
(Investor's Business Daily)
12:08PM Loading…
12:08PM
This Biotech Stock Soars 39%. Sanofi Is Buying It for $2.2 Billion.
(Barrons.com)
11:55AM
Dynavax Technologies Stock Soars on Buyout Buzz
(Schaeffer's Research)
11:24AM
Sanofi to Acquire Dynavax for $2.2 Billion, Expanding Vaccine Portfolio
(GuruFocus.com)
11:07AM
Stock Market Today: Dow Rises As Nike Jumps On Apple CEO Stake (Live Coverage)
(Investor's Business Daily)
11:07AM
Soft Weekly Jobless Claims Data
(Zacks)
10:49AM
Shares of Dynamax Are Up Nearly 40% Today. Here's Why The Stock Is Flying
(Investopedia)
10:35AM
Xmas Eve Jobless Claims: Still Accommodating
(Zacks)
09:59AM
Sanofi to Buy Dynavax for $2.2B to Boost Adult Vaccine Franchise
(Zacks)
09:36AM
KB Home downgraded, Costco upgraded: Wall Street's top analyst calls
(The Fly)
09:36AM
KB Home downgrade, Costco upgraded: Wall Street's top analyst calls
(The Fly)
09:24AM
BP to sell 65% of Castrol stake, Sanofi's $2.2B deal for Dynavax
(Yahoo Finance Video)
07:59AM
This Biotech Stock Is Soaring. Sanofi Is Buying It for $2.2 Billion.
(Barrons.com)
07:43AM
Biggest Mover Wednesday: Dynavax Stock Soars on $2.2 billion Acquisition Deal
(GuruFocus.com)
07:09AM
Nike, UiPath gain in premarket; Intel falls
(Investing.com)
07:04AM
U.S stocks on the move in Wednesday morning pre-market trading
(MarketWatch)
06:34AM Loading…
06:34AM
Sanofi to Buy Vaccine Maker Dynavax in $2.2 Billion Deal
(The Wall Street Journal)
04:57AM
Stock Market Today: Dow, S&P 500 and Nasdaq point to lower start ahead of shortened holiday trading session with U.S. jobless claims due later. Gold, silver and copper near record highs.
(MarketWatch)
01:23AM
Sanofi to Acquire Dynavax, Adding a Marketed Adult Hepatitis B Vaccine and Phase 1/2 Shingles Candidate to the Pipeline
(PR Newswire)
Dec-01-25 04:41PM
Moderna Slammed By 'Fear, Confusion' After FDA Alleges Covid Shots Killed 10
(Investor's Business Daily) -5.80%
12:35PM
Vaccine stocks take a hit as FDA official points to link between COVID-19 vaccines and rare heart condition in young men
(MarketWatch)
10:09AM
Moderna, BioNTech Slammed After FDA Links Covid Shots To 10 Deaths
(Investor's Business Daily)
Nov-19-25 04:01PM
Dynavax to Participate at the 8th Annual Evercore Healthcare Conference
(PR Newswire)
Nov-06-25 12:01AM
Dynavax Technologies Corp (DVAX) Q3 2025 Earnings Call Highlights: Strong Revenue Growth and ...
(GuruFocus.com) +6.70%
Nov-05-25 05:20PM
Dynavax Technologies (DVAX) Surpasses Q3 Earnings Estimates
(Zacks)
04:18PM
Dynavax Technologies: Q3 Earnings Snapshot
(Associated Press Finance)
04:01PM
Dynavax Reports Third Quarter 2025 Financial Results and Announces New $100 Million Share Repurchase Program
(PR Newswire)
04:00PM
Dynavax Enters Exclusive License Agreement for Vaxart's Novel Oral COVID-19 Vaccine Program
(PR Newswire)
Nov-04-25 04:15PM
Qiagen (QGEN) Q3 Earnings and Revenues Surpass Estimates
(Zacks)
Nov-03-25 05:55PM
Nuvation Bio Inc. (NUVB) Reports Q3 Loss, Tops Revenue Estimates
(Zacks)
Oct-22-25 04:01PM
Dynavax to Report Third Quarter 2025 Financial Results and Host Conference Call on November 5, 2025
(PR Newswire)
Oct-21-25 04:01PM
Dynavax Presents Positive Topline Data from Part 1 of Phase 1/2 Trial for Shingles Vaccine Candidate at IDWeek 2025 and Announces Initiation of Part 2 of Trial
(PR Newswire)
Sep-22-25 10:22AM
Amgen (AMGN) Moves 3.5% Higher: Will This Strength Last?
(Zacks)
Sep-02-25 04:05AM
Dynavax Technologies Corporation (DVAX) Reports Record $92M HEPLISAV-B Revenue, Raises 2025 Outlook
(Insider Monkey)
Aug-27-25 04:05PM
Dynavax to Participate in the 2025 Wells Fargo Healthcare Conference
(PR Newswire)
Aug-22-25 07:25AM
Dynavaxs shingles vaccine shows promise in trial against GSKs Shingrix
(Clinical Trials Arena)
Aug-21-25 08:00AM
Dynavax Announces Positive Topline Phase 1/2 Results Supporting Potential Best-in-Class Shingles Vaccine Profile
(PR Newswire) +5.09%
Aug-07-25 05:10PM
Dynavax Technologies (DVAX) Q2 Earnings and Revenues Beat Estimates
(Zacks) -6.60%
04:11PM
Dynavax Technologies: Q2 Earnings Snapshot
(Associated Press Finance)
04:00PM
Dynavax Reports Second Quarter 2025 Financial Results
(PR Newswire)
Aug-06-25 05:25PM
Protagonist Therapeutics (PTGX) Reports Q2 Loss, Lags Revenue Estimates
(Zacks)
Jul-29-25 04:02PM
Dynavax to Report Second Quarter 2025 Financial Results and Host Conference Call on August 7, 2025
(PR Newswire)
Jul-28-25 05:20PM
Exelixis (EXEL) Beats Q2 Earnings Estimates
(Zacks)
Jul-06-25 04:15AM
Citizens JMP Reiterates a Buy Rating on Dynavax Technologies (DVAX) With a Price Target of $31
(Insider Monkey)
Jun-11-25 11:01AM
Dynavax Stockholders Elect All Dynavax Director Nominees at 2025 Annual Meeting
(PR Newswire)
Jun-09-25 08:30AM
Deep Track Capital Sends Letter to Dynavax Technologies Shareholders Offering Final Perspectives on Why Change is Needed in the Boardroom
(Business Wire)
07:30AM
Dynavax Urges Stockholders to Support Its Director Nominees at June 11 Annual Meeting
(PR Newswire)
Jun-04-25 04:59PM
Dynavax Comments on Glass Lewis Recommendation
(PR Newswire)
09:27AM
Glass Lewis Recommends Shareholders Support Deep Track's Case for Board Change at Dynavax Technologies
(Business Wire)
May-28-25 04:10PM
Dynavax to Present at William Blair's 45th Annual Growth Stock Conference
(PR Newswire)
May-23-25 06:12PM
Deep Track Capital Comments on ISS Recommendation
(Business Wire)
01:44PM
Leading Independent Proxy Advisory Firm ISS Recommends Stockholders Vote "FOR" All Four of Dynavax's Highly Qualified Director Nominees
(PR Newswire)
May-15-25 04:00PM
Deep Track Capital Issues Letter to Fellow Dynavax Technologies Shareholders Detailing Critical Issues in Advance of Annual Meeting
(Business Wire)
May-12-25 07:30AM
Dynavax Files Investor Presentation Highlighting Superior Strategy and Board That is Delivering Strong Financial Results and Significant Long-Term Value
(PR Newswire)
May-09-25 08:38PM
/C O R R E C T I O N -- Dynavax Technologies/
(PR Newswire)
May-08-25 12:00PM
Dynavax Technologies (DVAX) Upgraded to Buy: Here's Why
(Zacks)
May-07-25 04:45PM
Dynavax Issues Statement and Mails Letter to Stockholders Emphasizing Record Financial Results and Continued Momentum
(PR Newswire) -10.99%
03:19AM
Dynavax Technologies Corp (DVAX) Q1 2025 Earnings Call Highlights: Record Revenue and Strategic ...
(GuruFocus.com)
May-06-25 05:15PM
Dynavax Technologies (DVAX) Reports Q1 Loss, Misses Revenue Estimates
(Zacks)
04:01PM
Dynavax Reports First Quarter 2025 Financial Results and Announces New Pipeline Programs
(PR Newswire)
08:00AM
Deep Track Capital Releases Investor Presentation on Dynavax Technologies
(Business Wire)
May-05-25 08:10AM
TG Therapeutics (TGTX) Lags Q1 Earnings Estimates
(Zacks)
May-01-25 08:00AM
Dynavax Announces Nationwide Harris Poll Survey Results Finding Americans Underestimate the Serious Consequences of Hepatitis B and Vaccine Protection Benefits
(PR Newswire)
Apr-29-25 07:30AM
Dynavax Highlights Superior Board Leadership Overseeing Long-Term Value Creation Strategy
(PR Newswire)
Apr-22-25 04:00PM
Dynavax to Report First Quarter 2025 Financial Results and Host Conference Call on May 6, 2025
(PR Newswire)
Apr-21-25 04:05PM
Deep Track Capital Files Definitive Proxy Statement and Sends Letter to Fellow Shareholders
(Business Wire)
Apr-17-25 09:17AM
GSK's Pentavalent Meningococcal Jab Recommended for Use by ACIP
(Zacks)
07:15AM
Dynavax Files Definitive Proxy Statement and Sends Letter to Stockholders
(PR Newswire)
Apr-16-25 09:48AM
MURA Soars as it Explores Strategic Options Post Cancer Study Failures
(Zacks) -6.66%
08:52AM
DTIL Gets FDA's Fast Track Tag for Hepatitis B Gene Therapy, Stock Up
(Zacks)
08:00AM
Deep Track Capital Comments on Dynavax Technologies Rejection of Most Recent Settlement Offer
(Business Wire)
Apr-15-25 10:20AM
Buy The Dips, Sell The Rips
(Seeking Alpha)
Apr-11-25 11:57AM
KROS Initiates Exploring Strategic Alternatives, Stock Gains 18.5%
(Zacks)
Apr-10-25 10:53AM
PHIO Stock Soars as Safety Panel Clears Skin Cancer Drug for Next Dose
(Zacks) -8.81%
09:58AM
ANIX Gets New Patent for Breast Cancer Vaccine Technology, Stock Up
(Zacks)
Apr-09-25 12:57PM
3 Biotech Stocks Holding Their Own
(Seeking Alpha)
10:01AM
RXRX Doses First Patient in Early-Stage B-Cell Lymphomas Study
(Zacks)
Apr-08-25 12:18PM
AtriCure Drops 25%: Bargain Or Caution Sign?
(Seeking Alpha) -5.92%
11:29AM
PCRX Stock Soars on Exparel Patent Settlement With Generic Players
(Zacks)
11:21AM
RYTM Stock Rises 17% on Meeting Goals in Hypothalamic Obesity Study
(Zacks)
Apr-07-25 10:53AM
AZN Gets EU Nod for Expanded Use of Two Separate Cancer Drugs
(Zacks)
Apr-04-25 01:45PM
Bayer's Vividion Initiates Dosing in Early-Stage Cancer Study
(Zacks)
01:10PM
AMGN's Uplizna Gets FDA Nod for 2nd Rare Autoimmune Disease Indication
(Zacks)
09:37AM
PCRX Doses First Patient in Phase II PCRX-201 Gene Therapy Study
(Zacks)
Apr-03-25 05:40PM
Dynavax Files Preliminary Proxy Statement
(PR Newswire)
11:27AM
SNY's Rilzabrutinib Gets FDA's Orphan Drug Tag for Two Rare Diseases
(Zacks)
Dynavax Technologies Corp. is a biopharmaceutical company, which engages in the provision of discovery, development, and commercialization of novel vaccines and immuno-oncology therapeutics. Its product includes HEPLISAV-B, which prevents infection caused by all known subtypes of hepatitis B virus in adults 18 years of age and older. The company was founded by Lawrence M. Lichtenstein, Dennis A. Carson, and Eyal Raz on August 29, 1996 and is headquartered in Emeryville, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Novack David FPresident & COOJan 15 '26Option Exercise9.83114,0001,120,280177,344Jan 20 04:33 PM
Novack David FPresident & COOJan 15 '26Sale15.64114,0001,782,96063,344Jan 20 04:33 PM
DAVID NOVACKOfficerJan 15 '26Proposed Sale15.64114,0001,782,727Jan 15 04:11 PM
Novack David FPresident & COODec 24 '25Option Exercise8.0330,000240,800141,451Dec 29 04:09 PM
Novack David FPresident & COODec 24 '25Sale15.4930,000464,700111,451Dec 29 04:09 PM
DAVID NOVACKOfficerDec 24 '25Proposed Sale15.4930,000464,700Dec 29 09:37 AM
Myers Scott DunsethDirectorAug 22 '25Buy10.823,80041,11635,004Aug 25 08:50 AM
Deep Track Biotechnology Maste10% OwnerAug 21 '25Sale11.031,094,99412,077,78416,696,492Aug 22 08:49 PM
Deep Track Biotechnology Maste10% OwnerAug 22 '25Sale10.59970,14310,273,81415,726,349Aug 22 08:49 PM
Novack David FPresident & COOMar 24 '25Option Exercise6.8010,00068,05018,078Mar 26 05:04 PM
Novack David FPresident & COOMar 24 '25Sale14.0010,000140,0008,078Mar 26 05:04 PM
DAVID NOVACKOfficerMar 24 '25Proposed Sale14.0010,000140,000Mar 24 04:23 PM
Novack David FPresident & COOMar 18 '25Sale13.5814,020190,3928,078Mar 20 06:15 PM
DAVID NOVACKOfficerMar 18 '25Proposed Sale13.5814,020190,386Mar 18 04:17 PM
Novack David FPresident & COOMar 07 '25Sale14.3932,764471,47422,098Mar 10 09:44 PM
DAVID NOVACKOfficerMar 07 '25Proposed Sale14.3932,764471,376Mar 07 05:16 PM
open in screener | open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR
Open in Screener

ZNTL

Zentalis Pharmaceuticals Inc

Last Close
Feb 13  •  04:00PM ET
2.39
Dollar change
+0.05
Percentage change
2.14 %
Healthcare • Biotechnology • USA • NASD
ZNTL Zentalis Pharmaceuticals Inc daily Stock Chart
Peers: BMY LLY PFE JNJ MRK AMGN GILD BIIB VRTX REGN
 | Held by: VTI VXF FESM PRFZ IWC VHT FSCC AVSC DFAS BTEC
Index- P/E- EPS (ttm)-2.08 Insider Own32.61% Shs Outstand72.25M Perf Week0.00%
Market Cap172.68M Forward P/E- EPS next Y-1.87 Insider Trans-4.44% Shs Float48.69M Perf Month-31.91%
Enterprise Value-67.56M PEG- EPS next Q-0.43 Inst Own56.55% Short Float8.27% Perf Quarter78.36%
Income-149.32M P/S6.43 EPS this Y21.73% Inst Trans-19.03% Short Ratio3.10 Perf Half Y61.49%
Sales26.86M P/B0.68 EPS next Y-2.33% ROA-38.39% Short Interest4.03M Perf YTD77.04%
Book/sh3.50 P/C0.62 EPS next 5Y12.28% ROE-49.18% 52W High3.95 -39.49% Perf Year-1.65%
Cash/sh3.89 P/FCF- EPS past 3/5Y14.39% -12.89% ROIC-51.56% 52W Low1.01 136.63% Perf 3Y-88.32%
Dividend Est.- EV/EBITDA- Sales past 3/5Y- - Gross Margin96.65% Volatility7.40% 10.74% Perf 5Y-93.44%
Dividend TTM- EV/Sales-2.52 EPS Y/Y TTM17.54% Oper. Margin-567.95% ATR (14)0.26 Perf 10Y-
Dividend Ex-Date- Quick Ratio7.76 Sales Y/Y TTM-33.76% Profit Margin-555.80% RSI (14)48.26 Recom2.11
Dividend Gr. 3/5Y- - Current Ratio7.76 EPS Q/Q34.48% SMA20-9.19% Beta1.71 Target Price5.31
Payout- Debt/Eq0.16 Sales Q/Q- SMA5011.16% Rel Volume0.19 Prev Close2.34
Employees166 LT Debt/Eq0.15 EarningsNov 10 AMC SMA20047.25% Avg Volume1.30M Price2.39
IPOApr 03, 2020 Option/ShortYes / Yes EPS/Sales Surpr.29.90% - Trades Volume245,060 Change2.14%
Date Action Analyst Rating Change Price Target Change
Aug-12-24Upgrade Wedbush Underperform → Neutral $4
Jun-20-24Downgrade UBS Buy → Neutral $28 → $5
Jun-18-24Downgrade Wells Fargo Overweight → Equal Weight
Jun-18-24Downgrade Wedbush Neutral → Underperform $15 → $4
Jun-18-24Downgrade Morgan Stanley Overweight → Equal-Weight $38 → $8
Jun-18-24Downgrade Jefferies Buy → Hold $42 → $6
Nov-08-23Downgrade Wedbush Outperform → Neutral $38 → $12
Nov-07-23Downgrade Leerink Partners Outperform → Market Perform $15
Jul-12-22Initiated Cowen Outperform
Apr-06-22Initiated Wells Fargo Overweight $67
Show Previous Ratings
Feb-03-26 04:05PM
Zentalis Pharmaceuticals to Participate in Upcoming Investor Conference
(GlobeNewswire) +12.35% -9.57%
Jan-13-26 08:45AM
Mitsui Sumitomo Continues to Build WR Berkley Stake
(24/7 Wall St.)
Jan-12-26 10:35AM
Fast-Tracking the $537B Cancer Cure: How Accelerated Approvals Reshaping Oncology in 2026
(PR Newswire) -6.68%
Jan-06-26 08:00AM
Zentalis Pharmaceuticals Provides Corporate Update and Highlights Key Milestones and Expected Momentum in the Azenosertib Development Program for 2026
(GlobeNewswire) +29.93%
Nov-10-25 04:05PM
Zentalis Pharmaceuticals Reports Third Quarter 2025 Financial Results and Operational Progress
(GlobeNewswire) +6.06%
05:25PM Loading…
Nov-03-25 05:25PM
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
(GlobeNewswire) -8.33%
08:15AM
Zentalis Pharmaceuticals to Participate in Upcoming Investor Conferences
(GlobeNewswire)
Oct-13-25 04:05PM
Zentalis Pharmaceuticals Announces Four Azenosertib Posters Presentations at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
(GlobeNewswire)
Oct-01-25 05:20PM
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
(GlobeNewswire) +7.79%
Sep-02-25 05:00PM
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
(GlobeNewswire)
Aug-28-25 04:15PM
Zentalis Pharmaceuticals to Participate in Upcoming Investor Conferences
(GlobeNewswire)
Aug-26-25 04:05PM
Zentalis Pharmaceuticals Appoints James B. Bucher, JD, as Chief Legal Officer and Corporate Secretary
(GlobeNewswire)
Aug-06-25 04:05PM
Zentalis Pharmaceuticals Reports Second Quarter 2025 Financial Results and Operational Progress
(GlobeNewswire) +5.07%
Jul-01-25 05:00PM
Zentalis Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
(GlobeNewswire)
Jun-02-25 05:00PM
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
(GlobeNewswire) +5.79% +6.25%
04:05PM Loading…
May-14-25 04:05PM
Zentalis Pharmaceuticals Reports First Quarter 2025 Financial Results and Operational Progress
(GlobeNewswire) +5.88%
May-01-25 05:00PM
Zentalis Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
(GlobeNewswire)
Apr-28-25 08:00AM
Zentalis Pharmaceuticals Announces First Patient Dosed in DENALI Part 2 Clinical Trial of Azenosertib in Patients with Cyclin E1+ PROC
(GlobeNewswire)
Apr-23-25 04:05PM
Zentalis Pharmaceuticals Announces Poster Presentation at 2025 ASCO Annual Meeting
(GlobeNewswire)
Apr-01-25 05:30PM
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
(GlobeNewswire) -12.58%
Mar-26-25 04:05PM
Zentalis Pharmaceuticals Reports Full Year 2024 Financial Results and Operational Updates
(GlobeNewswire) -5.88%
Mar-25-25 04:40PM
Zentalis Pharmaceuticals to Present Multiple Posters at the American Association for Cancer Research (AACR) Annual Meeting 2025
(GlobeNewswire) -5.56%
Mar-15-25 11:25AM
Zentalis Pharmaceuticals Presents Updated Clinical Data at the Society of Gynecologic Oncology 2025 Annual Meeting on Women's Cancer
(GlobeNewswire)
Mar-03-25 05:00PM
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
(GlobeNewswire) -7.25%
08:00AM
Zentalis Pharmaceuticals Announces Multiple Data Presentations at Society of Gynecologic Oncology 2025 Annual Meeting on Women's Cancer
(GlobeNewswire)
Feb-24-25 04:05PM
Zentalis Pharmaceuticals to Participate in Upcoming Investor Conferences
(GlobeNewswire)
Feb-21-25 12:21AM
Zentalis Pharmaceuticals (ZNTL): Among Cheapest Stocks Insiders Are Buying Recently
(Insider Monkey) -6.07%
Feb-03-25 05:42PM
Zentalis Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
(GlobeNewswire)
09:35AM
Zentalis Pharmaceuticals (ZNTL) Loses -46.3% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
(Zacks)
Jan-30-25 10:20AM
Zentalis price target lowered to $10 from $20 at Oppenheimer
(TipRanks) -12.17%
07:00AM Loading…
Jan-29-25 07:00AM
Zentalis Pharmaceuticals Shares Updated Clinical Data Demonstrating Meaningful Azenosertib Activity in Cyclin E1+, Platinum-Resistant Ovarian Cancer
(GlobeNewswire) -21.25%
Jan-28-25 04:05PM
Zentalis Pharmaceuticals Announces Strategic Restructuring to Support Late-Stage Azenosertib Development
(GlobeNewswire)
Jan-09-25 12:00PM
Zentalis Pharmaceuticals (ZNTL) Upgraded to Strong Buy: What Does It Mean for the Stock?
(Zacks)
07:00AM
Zentalis Pharmaceuticals Announces Azenosertib Fast Track Designation and Virtual Corporate Event to Present Updated Data from Azenosertib Clinical Studies
(GlobeNewswire)
Jan-02-25 04:53PM
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
(GlobeNewswire) +8.00%
Dec-12-24 07:00AM
Zentalis Pharmaceuticals Announces Key Management Appointments
(GlobeNewswire) -10.57%
Dec-02-24 04:35PM
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
(GlobeNewswire) -8.20%
Nov-13-24 08:00AM
Zentalis Pharmaceuticals Announces Executive Leadership Changes Supporting Planned Registrational Clinical Studies of Azenosertib
(GlobeNewswire) +5.66%
Nov-01-24 07:04PM
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
(GlobeNewswire) +21.61% +12.35%
Oct-18-24 03:05PM
State Street Corp's Strategic Reduction in Zentalis Pharmaceuticals Holdings
(GuruFocus.com)
Oct-07-24 03:03PM
FMR LLC Adjusts Its Stake in Zentalis Pharmaceuticals Inc
(GuruFocus.com) -7.72%
Sep-17-24 12:15PM
FDA lifts partial clinical hold on Zentalis Pharmas cancer WEE1 inhibitor
(Pharmaceutical Technology) +11.41%
Sep-16-24 09:00AM
FDA Removes Partial Hold On Zentalis Pharmaceuticals' Azenosertib Studies In Patients With Gynecological Cancers
(Benzinga) +13.58%
07:00AM
Zentalis Pharmaceuticals Announces FDA Has Lifted Partial Clinical Hold on Azenosertib Studies
(GlobeNewswire)
Sep-09-24 07:00AM
Zentalis Pharmaceuticals to Present Preclinical Azenosertib Data at ESMO 2024
(GlobeNewswire)
Sep-03-24 04:40PM
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
(GlobeNewswire) -6.92%
Aug-26-24 11:58AM
Zentalis (ZNTL) Plunges More Than 70% in 3 Months: Here's Why
(Zacks)
Aug-09-24 02:53PM
ZNTL Stock Earnings: Zentalis Pharma Misses EPS for Q2 2024
(InvestorPlace) -9.37%
07:00AM
Zentalis Pharmaceuticals Reports Second Quarter 2024 Financial Results and Operational Progress
(GlobeNewswire)
Aug-01-24 06:00PM
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
(GlobeNewswire) -5.00%
Jul-01-24 06:00PM
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
(GlobeNewswire) -14.80%
Jun-19-24 10:23AM
Zentalis (ZNTL) Tanks After FDA Puts 3 Cancer Studies on Hold
(Zacks)
04:52AM
FDA places partial clinical hold on Zentalis trials of azenosertib for cancer
(Clinical Trials Arena)
Jun-18-24 07:00AM
Zentalis Pharmaceuticals Provides Update on Azenosertib Clinical Development Program
(GlobeNewswire) -50.66%
Jun-03-24 06:00PM
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
(GlobeNewswire)
Jun-01-24 02:43AM
Insider Selling at Zentalis Pharmaceuticals Inc (ZNTL): President, Interim CFO Cam Gallagher ...
(GuruFocus.com)
May-30-24 07:00AM
Zentalis Pharmaceuticals to Present at the Jefferies Global Healthcare Conference
(GlobeNewswire)
May-29-24 07:00AM
Zentalis Pharmaceuticals Announces Appointment of Accomplished Oncology Drug Developer Luke Walker, M.D., to Board of Directors
(GlobeNewswire)
May-23-24 05:01PM
Zentalis Pharmaceuticals to Present Promising Results from Phase 1 Trial of Azenosertib and Gemcitabine in Relapsed or Refractory Osteosarcoma at 2024 American Society of Clinical Oncology Annual Meeting
(GlobeNewswire) -5.84%
May-14-24 07:00AM
Zentalis Pharmaceuticals to Present at TD Cowen 5th Annual Oncology Innovation Summit
(GlobeNewswire)
May-08-24 10:27AM
Stifel Adjusts Price Target on Zentalis Pharmaceuticals to $32 From $36, Maintains Buy Rating
(MT Newswires)
May-07-24 09:04PM
Zentalis Pharmaceuticals Reports Q1 2024 Earnings: Surpasses Revenue Forecasts with Strategic ...
(GuruFocus.com) +5.03%
01:54PM
ZNTL Stock Earnings: Zentalis Pharma Beats EPS, Beats Revenue for Q1 2024
(InvestorPlace)
07:00AM
Zentalis Pharmaceuticals Reports First Quarter 2024 Financial Results and Operational Progress
(GlobeNewswire)
May-01-24 05:30PM
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
(GlobeNewswire)
Apr-02-24 04:05PM
Zentalis Pharmaceuticals to Highlight Preclinical Data Demonstrating that WEE1 Inhibitor Azenosertib Exerts Synergistic Anti-tumor Activity with KRAS(G12C) Inhibitors at AACR Annual Meeting 2024
(GlobeNewswire) -10.54% +8.25%
Apr-01-24 05:30PM
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
(GlobeNewswire)
Mar-01-24 06:00PM
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
(GlobeNewswire)
Feb-28-24 09:55AM
Wall Street Analysts Think Zentalis Pharmaceuticals, Inc. (ZNTL) Could Surge 136.44%: Read This Before Placing a Bet
(Zacks) +5.30%
07:00AM
Zentalis Pharmaceuticals to Participate in Upcoming Investor Conferences
(GlobeNewswire)
Feb-27-24 07:01PM
Zentalis Pharmaceuticals Inc (ZNTL) Reports Full Year 2023 Financial Results and Provides ...
(GuruFocus.com)
07:00AM
Zentalis Pharmaceuticals Reports Full Year 2023 Financial Results and Operational Updates
(GlobeNewswire)
Feb-14-24 09:35AM
Down -19.06% in 4 Weeks, Here's Why You Should You Buy the Dip in Zentalis Pharmaceuticals, Inc. (ZNTL)
(Zacks) +10.34%
Feb-13-24 07:00AM
Zentalis Pharmaceuticals to Participate in the Oppenheimer Healthcare Life Sciences Conference
(GlobeNewswire) -5.83%
Feb-08-24 12:00PM
What Makes Zentalis Pharmaceuticals, Inc. (ZNTL) a New Buy Stock
(Zacks)
Feb-05-24 11:26PM
Insider Sell: President Cam Gallagher Sells 11,552 Shares of Zentalis Pharmaceuticals Inc (ZNTL)
(GuruFocus.com)
Feb-01-24 05:00PM
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
(GlobeNewswire)
Jan-25-24 07:00AM
Zentalis Pharmaceuticals Strengthens Management Team with Key Appointments
(GlobeNewswire)
Jan-08-24 07:00AM
Immunome Exclusively Licenses Zentalis ROR1 Antibody-Drug Conjugate and Proprietary Technology Platform
(Business Wire) +7.15%
Jan-02-24 04:49PM
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
(GlobeNewswire) +5.54%
Dec-01-23 05:39PM
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
(GlobeNewswire)
Nov-13-23 09:03PM
Director David Johnson's Strategic Purchase of Zentalis Pharmaceuticals Inc Shares
(GuruFocus.com) +14.42%
Nov-09-23 07:00AM
Zentalis to Participate in Investor Call Focused on Ovarian Cancer with Gynecologic Oncology Key Opinion Leader Joyce F. Liu, M.D., MPH, Hosted by TD Cowen
(GlobeNewswire)
Nov-06-23 07:13PM
Zentalis Pharmaceuticals Inc (ZNTL) Reports Q3 2023 Financial Results and Operational Updates
(GuruFocus.com) -30.20% -18.27%
07:18AM
Zentalis Pharmaceuticals Reports Third Quarter 2023 Financial Results and Operational Updates
(GlobeNewswire)
Nov-01-23 04:52PM
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
(GlobeNewswire)
Oct-07-23 05:00AM
Insider Sell: Chief Medical Officer Carrie Brownstein Sells 10,628 Shares of Zentalis ...
(GuruFocus.com)
Oct-02-23 04:27PM
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
(GlobeNewswire)
Sep-14-23 01:02AM
Director Jan Skvarka Sells 5,000 Shares of Zentalis Pharmaceuticals Inc (ZNTL)
(GuruFocus.com)
Sep-06-23 07:00AM
Zentalis Pharmaceuticals to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference
(GlobeNewswire)
Sep-01-23 04:37PM
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
(GlobeNewswire) -6.34%
Aug-09-23 07:00AM
Zentalis Pharmaceuticals Reports Second Quarter 2023 Financial Results and Operational Updates
(GlobeNewswire)
Aug-01-23 04:28PM
Zentalis Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
(GlobeNewswire)
07:00AM
Zentalis Pharmaceuticals Appoints Kimberly Freeman as Chief Strategy Officer
(GlobeNewswire)
Jun-15-23 06:01AM
Zentalis Pharmaceuticals Announces Pricing of Underwritten Offering of Common Stock
(GlobeNewswire) +12.67%
Jun-06-23 06:00AM
Zentalis Announces Intermittent Azenosertib Monotherapy Dosing Nearly Doubles Efficacy Over Continuous Dosing
(GlobeNewswire)
Jun-02-23 02:34PM
Why Shares of Zentalis Pharmaceuticals Dropped This Week
(Motley Fool)
May-26-23 12:33PM
Wells Fargo Predicts up to 70% Rally for These 2 Stocks Heres Why They Have Solid Upside
(TipRanks) +10.64%
10:53AM
Zentalis Gears Up for Phase 3 Study of Azenosertib after Positive Phase 1b Outcomes
(Benzinga)
May-25-23 05:38PM
Zentalis Announces Presentation of Positive Phase 1b Data Demonstrating Durable Responses and Favorable Safety Profile of Azenosertib in Combination with Chemotherapy at the 2023 ASCO Annual Meeting
(GlobeNewswire)
Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering and developing clinically differentiated, novel small molecule therapeutics targeting fundamental biological pathways of cancer. It develops a broad pipeline of product candidates with an initial focus on validated oncology targets with the potential to address large patient populations. The company was founded by Kevin D. Bunker and Cam Gallagher on December 23, 2014 and is headquartered in San Diego, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Bruns IngmarChief Medical OfficerFeb 06 '26Sale2.432,9627,19733,667Feb 10 09:10 PM
Bruns IngmarChief Medical OfficerFeb 09 '26Sale2.3933580233,332Feb 10 09:10 PM
Vultaggio VincentPAO and PFOFeb 06 '26Sale2.4329,95172,772156,779Feb 10 09:10 PM
Vultaggio VincentPAO and PFOFeb 10 '26Sale2.426,89416,699146,506Feb 10 09:10 PM
Vultaggio VincentPAO and PFOFeb 09 '26Sale2.393,3798,086153,400Feb 10 09:10 PM
EASTLAND JULIA MARIECEO & PresidentFeb 06 '26Sale2.437,86619,11280,022Feb 10 09:09 PM
EASTLAND JULIA MARIECEO & PresidentFeb 09 '26Sale2.398892,12779,133Feb 10 09:09 PM
Vultaggio VincentPAO and PFOFeb 02 '26Sale2.552,5406,477187,286Feb 04 08:27 PM
Vultaggio VincentPAO and PFOFeb 03 '26Sale2.525561,398186,730Feb 04 08:27 PM
WALTERS GROUP10% OwnerDec 31 '25Buy1.206,459,9737,751,96813,509,973Jan 08 04:57 PM
Matrix Capital Management Comp10% OwnerDec 15 '25Sale1.337,500,0009,975,0006,459,973Dec 15 05:24 PM
Myers Scott DunsethDirectorApr 30 '25Buy1.4021,00029,373281,192Apr 30 05:07 PM
open in screener | open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR
Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2026 Finviz.com. All Rights Reserved.